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Abstract: Aarskog-Scott syndrome (AAS) is a rare developmental disorder which primarily affects 
males and has a relative prevalence of 1 in 25,000 in the general population. AAS patients usually 
present with developmental complications including short stature and facial, skeletal and urogenital 
anomalies. The spectrum of genotype-phenotype correlations in AAS is unclear and mutations of the 
FGD1 gene on the proximal short arm of chromosome X account for only 20% of the incidence of the 
disorder. Failure to identify pathogenic variants in patients referred for FGD1 screening suggests 
heterogeneity underlying pathophysiology of the condition. Furthermore, overlapping features of AAS 
with several other developmental disorders increase the complexity of diagnosis. Cytoskeletal 
signaling may be involved in the pathophysiology of AAS. The FGD1 protein family has a role in 
activation of CDC42 (Cell Division Control protein 42 homolog) which has a core function in 
remodeling of extracellular matrix and the transcriptional activation of many modulators of 
development. Therefore, mutations in components in the EGFR1 (Epidermal Growth Factor Receptor 
1) signaling pathway, to which CDC42 belongs, may contribute to pathophysiology. Parallel 
sequencing strategies (so-called next generation sequencing or high throughput sequencing) enables 
simultaneous production of millions of sequencing reads that enormously facilitate cost-effective 
identification of cryptic mutations in heterogeneous monogenic disorders. Here we review the source 
of phenotypic and genetic heterogeneity in the context of AAS and discuss the applicability of next 
generation sequencing for identification of novel mutations underlying AAS. 
Keywords: Aarskog-Scott Syndrome; FGD1 gene; genetic heterogeneity; phenotypic heterogeneity; 
next generation sequencing 
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1. Introduction 
Aarskog-Scott syndrome (AAS, OMIM #305400) (also known as faciogenital dysplasia) is a 
complex developmental disorder initially described by Aarskog in a Finnish pedigree [1] and later by 
Scott [2]. Patients with AAS present with a range of developmental complications including short 
stature, hypertelorism, ptosis, long philtrum, micrognathia, broad nasal bridge, clinodactyly of the little 
finger and genitourinary abnormalities including cryptorchidism and shawl scrotum [3]. Causal 
genetic variants underlying AAS pathophysiology map to the proximal short arm of chromosome X 
(Xq11.22) [4] and, to date, 61 different mutations across the 18 exons of the FGD1 gene are reported 
as pathogenic in the context of the condition. The FGD1 mutational spectrum includes 32 missense 
mutations, 16 frameshift variants, 6 nonsense variants, 4 splice site variants, 1 in-frame deletion and 2 
out of frame deletions [5–10]. 
While only a limited number of the reported cases have been molecularly confirmed (~35), the 
population incidence of two to three patients with a proven FGD1 mutation per year is suggestive of 
world population prevalence of 1/25000 [5]. It is notable that the reported mutations only describe 
20% of the known cases of AAS [6] and the spectrum of genotype-phenotype correlations is unclear. 
Failure to identify pathogenic variants in patients who are referred for FGD1 mutation analysis must 
reflect extensive clinical and genetic heterogeneity in AAS. In particular, the phenotypic features of 
the condition overlap with several other developmental disorders. Since it is now possible to undertake 
cost-effective sequencing of genes of clinical interest, exomes, or indeed whole genomes, there is 
greatly increased confidence that phenotypic overlaps can be resolved and underlying genetic causal 
variation understood for AAS and AAS-like syndromes. We review here sources of phenotypic and 
genetic heterogeneity underlying the condition and discuss the extent to which next generation 
sequencing can be utilized to detect new mutations in AAS. 
 
2. Phenotypic presentation 
 
A diagnosis of AAS is normally established through the Teebi criteria [7] by evaluating 
phenotypic features in a mother and an affected son. In this approach the clinical manifestation of the 
condition is studied in a tiered fashion and diagnosis is established in the presence of all primary and 
most secondary criteria. A detailed list of the diagnostic criteria and clinical features which 
differentiate AAS from similar syndromes is provided in Table 1. Short stature, hypertelorism and fold 
of the lower lip are the primary features present in nearly all cases [8]. Brachydactyly, interdigital 
webbing, shawl scrotum, long philtrum and mild facial hypoplasia are secondary features observed in 
almost 80% of cases. Additional phenotypic manifestations which include cryptorchidism, inguinal 
hernia, downward eye slant and ptosis are present in only a fraction of patients and therefore deemed 
secondary for diagnosis. AAS patients usually present with delayed growth in early childhood, but 
achieve developmental milestones later in life [9]. AAS predominantly influences males and 
phenotypic complications are attenuated in females. Two separate reports identify impaired executive 
attentional processes including attention deficit/hyperactivity disorder (ADHD) [10] and mania [11]. 
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Table 1. Teebi tiered criteria for differential diagnosis of Aarskog-Scott Syndrome [12,17]. 
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AAS Primary Diagnostic Criteria 
Hypertelorism + + + + variable + + pronounced + variable 
Short nose/ anteverted nares + + + + mild + + +/− 
Maxillary hypoplasia + + + + − + +/− asymmetry 
Crease below lower lip + − − − + − − 
Short, broad hands + + + − − +/− +/− 
Mild, interdigital webbing + + − + + + − 
Short stature + + + − − − − 
Shawl scrotum + + − − + + + 
Short fifth finger/ clinodactyly + + + − − + + 
AAS Secondary Criteria 
Widow’s peak + + − + + + − 
Ptosis + − − +/− + + − 
Downward slant of palpebral 
fissures 
+ − − +/− + + − 
Abnormal auricle/Fleshy 
lobules 
+ + + + + + − 
Joint hyperextensibility + + − + − − +/− 
Broad feet with bulbous toes + + + − + variable + − long toes 
Cryptorchidism/inguinal 
umbilical hernia 
+ − + + − + − 
Large head/bossing +/− − + − − + 
brachycephaly 
+ 
Craniosynostosis − − − − − − + 
Broad or bifid nasal tip − − − + + + − 
Thick eyebrows − − − − + + − 
True syndactyly − − − + toes + 3 and 4 
fingers 
−  
Nail groove − − − − − − +/− 
Broad thumb/toe, duplications 
or polydactyly 
− − − − + − + 
Short limbs − − + − − − + 
Hypoplastic genitalia − − + − −/+ − − 
Hypospadias +/− − − + constant + − − 
Laryngeal complications − − − + − − − 
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Vertebral anomalies + − + − − − − 
Intelligence Usually 
Normal 
Normal Normal Variable Normal Normal Variable 
Affected sex Mostly 
males 
Both Both Both Both Both Mostly females 
Inheritance AD, 
XL 
AR AD, 
AR 
AD, XL AR AD ?AD, ?XL 
Key: AD: Autosomal dominant, AR: Autosomal recessive, XL: X-linked 
 
3. Phenotypic heterogeneity: related syndromes and differential diagnosis 
 
Similarities between the phenotypic faciogenital characteristics of AAS patients and other 
developmental disorders including Noonan syndrome, SHORT syndrome (Short stature, 
hyperextensibility, hernia, ocular depression, Rieger anomaly, and teething delay) and Robinow 
syndrome increase the complexities of diagnosis. Noonan (OMIM #163950) and Noonan-like 
syndromes in particular show significant similarities to AAS. Hypertelorism, genital anomalies and 
ptosis are present in both conditions, however, additional characteristics of Noonan syndrome 
including heart abnormalities and lymphatic malformations contribute to unambiguous diagnosis [12]. 
Similarly, Robinow syndrome (OMIM #268310) presents with many manifestations identical to AAS. 
While short stature, hypertelorism and facial anomalies are seen in both conditions, shawl scrotum is 
restricted to AAS patients and Robinow patients present characteristic shortening of mesomelic limbs [13]. 
Furthermore, LEOPARD syndrome (OMIM #151100) in which patients present with Lentigines, 
Electrocardiographic condition defect, Ocular hypertelorism, Pulmonary stenosis, Abnormalities of 
genitals, Retarded growth and Deafness shares some phenotypic characteristics of AAS. LEOPARD 
syndrome appears to occur sporadically and therefore differential diagnosis is usually established 
based on mode of inheritance [14]. Since related syndromes may share phenotypic features with AAS 
differential diagnosis therefore requires careful consideration of a spectrum of phenotypic features. 
Establishment of a robust AAS diagnosis requires consideration of the age and gender of the patient [15]. 
Furthermore, resolution of any developmental delay issues during later stages of development is 
indicative of AAS. Female AAS patients, arising through X-linked recessive inheritance, present with 
attenuated features of the condition. This can be attributed to skewed X-inactivation in which the causal 
X-linked allele is subject to strong selection to become inactivated [16]. The extent of non-random X-
inactivation in the context of AAS is poorly understood and merits further investigation. Genitourinary 
abnormalities are almost always restricted to male patients.  
Rare AAS cases with additional complications including spina bifida occulta (incomplete closure 
of the spine and surrounding tissues), cervical spine abnormalities [17], scoliosis (abnormal curve of 
spine) [18], camptodactyly (fixed flexion deformity of the joints in toes) and lymphoedema [19], 
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macrochidism (abnormally enlarged testis) [20] and ocular complications (optic nerve hypoplasia, 
retinal vessel tortuosity, deficient ocular elevation, hyperopia and anisometropia) [21–23] are also 
reported. 
The clinical spectrum of AAS phenotypes and overlap with related syndromes is sufficiently broad 
to complicate diagnosis and in many cases a definitive diagnosis can only be established through 
molecular methods such as targeted sequencing [24]. 
 
4. The functional role of FGD1 
 
At least 61 mutations known to be involved in AAS map to the FGD1 gene which is located at the 
proximal short arm of chromosome X (Xp11.22) [25]. FGD1 encodes a member of the Dbl family of 
guanine nucleotide exchange factors (GEFs) which play important roles in cell division through 
activation of Rho GTPase cell division cycle 42 (CDC42) [26]. Dbl family GEFs comprise a highly 
conserved Dbl homology (DH) domain and a tandem pleckstrin homology (PH) domain that functions 
immediately upstream of Rho GTPases. Following stimuli from growth factor or cytokine receptors, 
the PH domain of the protein targets intracellular Rho-GDP complexes and the catalytic activity of 
DH domain phosphorylates Rho-GDP. The activated Rho-GTP complex initiates a cascade of 
downstream signaling leading to transcription activation, regulation of translation and membrane 
trafficking (Figure 1; reviewed in [27]). The precise mechanisms by which FGD1 mutations cause the 
dysmorphic craniofacial features of AAS is unclear, but it is believed that pathogenic mutations of 
FGD1 disrupt CDC42 signaling during skeletogenesis and the disturbed extracellular matrix 
remodeling results in characteristic faciogenital anomalies of AAS [28].  
 
Figure 1. Domain structure and signaling cascade of Dbl family GEFs in the 
regulation of Rho-GTPase function. (AI: autoinhibitory domain; Gβγ: Gβγ domain; DH: 
Dbl homology domain; PH: Pleckstin homology domain). Signaling cascade initiates upon 
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activation of range of cell surface receptors including cytokine receptors, growth factor 
receptors and adhesion receptors where the PH domain of Dbl family GEFs are thought to 
have interactions with cell-membrane phospholipids. Stimuli from the receptor lead to 
conformational change in Dbl family GEFs which lead to activation of PH domain through 
relief of intramolecular interactions. DH domain in turn facilitate activation of Rho GTPase 
through exchange of GDP to GTP. Activated Rho-GTPase subsequently mediates 
activation of variety of downstream pathways including transcription activation, 
translation regulation and membrane trafficking. 
5. AAS mode of inheritance 
 
Segregation analysis indicates that AAS is typically an X-linked recessive condition, however sex-
influenced autosomal dominant and autosomal recessive patterns of inheritance have also been 
reported [21,29]. An autosomal recessive form is recurrently observed in the Kuwaiti Bedouin tribe 
with prevalence of 1 in 625 [25]. The phenotypic spectrum in this tribe, where consanguineous marriage 
is common, is consistent with AAS and indicates a founder effect in this population. In addition, several 
reports have identified a sex influenced autosomal dominant pattern for AAS [23,30,31] with at least 
one report of complete phenotypic expression in a mother and her son who both had a balanced X: 
autosome translocation [23]. The determination of carrier status in female patients is usually 
challenging as skewed X-inactivation results in random and attenuated expression [32]. The detailed 
characteristics of known FGD1 mutations underlying faciogenital dysplasias extracted from the LOVD 
v.3.0 database [33] is provided in Supplementary Table S1. 
 
6. Discussion 
 
Increasing evidence suggests the Dbl family of proteins play critical roles in essential cell 
processes, including cytoskeleton organization, regulation of vesicular endocytosis and intracellular 
signal transduction. Mutations in genes encoding these proteins are associated with variety of 
developmental syndromes and their pathologies display overlapping features with AAS [34]. Because 
known FGD1 mutations only explain ~20% of cases the pathologic mutations underlying most cases 
remain undefined and mutations in genes within this family, or related pathways, are strong candidates. 
The variability in disease expression and the extensive phenotypic similarities between AAS and 
RASopathies (Noonan syndrome, LEOPARD syndrome, cardio-facio-cutaneous syndrome and 
Costello syndrome) suggest possibilities for identifying additional AAS causal genes in related 
pathways. Germline mutations of the RAS/MAPK signaling pathway are implicated in RASopathies 
and all recently discovered mutations in the context of RASopathies map to components of mitogen-
activated protein kinase [35].Genotype-phenotype correlations in AAS are poorly understood and it 
seems plausible that some cases without molecular diagnosis arise through mutations in key 
modulators of development which function both upstream and downstream of the FGD1 protein 
(Figure 2 and Table 2) [36,37].  
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Figure. 2 Schematic representation of the human FGD1 interactome compiled in 
STRING v.10 [38]. Neighboring proteins with direct interactions usually function in the 
same signaling pathway and are therefore responsible for the same, or phenotypically 
similar, disorders. The FGD1 interactome highlights the genes whose protein products are 
known to have direct protein-protein interaction with CDC42, the key protein in EGFR1 
signaling pathway that implicated in AAS pathophysiology. 
Table 2. Predicted FGD1 signaling partners and their functions [38]. 
Gene/ 
Protein ID 
Name Function 
CDC42 Cell division cycle 42 Plasma membrane-associated small GTPase which cycles between an 
active GTP-bound and an inactive GDP-bound state. 
FGD3 FYVE, RhoGEF and PH 
domain containing 3 
Member of the Ras-like family of Rho and Rac proteins- may activate 
CDC42 
MCF2 Cell line derived transforming 
sequence 
Encodes a GEF oncoprotein that regulates activation of some members 
of the Rho family of small GTPases. 
PLEK Pleckstrin Major protein kinase C substrate of platelets. 
FAM120C Family with sequence 
similarity 120C 
– 
FGD4 FYVE, RhoGEF and PH 
domain containing 4 
Member of the Ras-like family of Rho and Rac proteins. Activates 
CDC42 and plays an important role in regulating the actin cytoskeleton 
and cell shape. 
FARP2 FERM, RhoGEF and 
pleckstrin domain protein 2 
Encodes a GEF that activate RAC1. May have attenuated activity. 
FGD5 FYVE, RhoGEF and PH 
domain containing 5 
Member of the Ras-like family of Rho and Rac proteins. Activates 
CDC42. Possibly plays a role in regulating the actin cytoskeleton and 
cell shape. 
BTRC Beta-transducin repeat 
containing E3 ubiquitin 
protein ligase 
Encodes one member of F-box protein that constitutes one of the four 
subunits of SCFs (SKP1-cullin-F-box) that function in phosphorylation-
dependent ubiquitination. 
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Comprehensive molecular diagnosis of AAS patients may need to consider sources of causal 
variation that may be missed by, for example, exome sequencing which excludes intronic variants 
(including splice site branch points). Therefore, in some cases gene resequencing or whole-genome 
analysis may be the most suitable approach for establishing the molecular basis for pathophysiology 
of the condition. The identification of a branch point variant within an intronic region adjacent to exon 
13 of FGD1 [39] in an AAS case lends further support to effectiveness of whole gene/genome 
sequencing. In the latter study the causative variant was identified only upon relaxing the filtering 
criteria to include larger intronic segments. In-silico analysis predicted that the identified aberration of 
a splice site leads to the skipping of exon 13 and disruption in the reading frame introducing a 
premature stop codon [40].  
The very large number of potentially deleterious variants identified by sequencing presents 
challenges. Even with rigorous filtering and prioritization procedures there may be difficulties in 
firmly establishing underlying pathogenic variants. In a recent study [41] into the effectiveness of 
clinical whole-genome sequencing of patients with uncertain molecular diagnosis, the authors 
established that causal variants could be firmly identified in only 34% of patients with Mendelian 
disorders. In targeted high-throughput sequencing of heterogeneous disorders the probability of 
successful identification of causal variants is directly correlated with the number of major clinical 
features presented by the patient. The latter notion is demonstrated in a study by Redin et al. [30] where 
comparison of clinical phenotypes between patients with more than one detected pathogenic variant 
and those with either one or no suspicious pathogenic variant clearly demonstrated the importance of 
precise phenotyping in facilitating accurate identification of underlying causal mutations. 
Another consideration in the analysis of high-throughput sequencing data is the presence of high 
frequency pathologic variants in isolated populations (e.g. the Kuwaiti Bedouin tribe) that might be 
otherwise neglected during filtering and prioritization processes. This challenge could be addressed 
through application of high-throughput autozygosity mapping [31] and haplotype-based variant 
callers [42]. 
More than 21 Guanine nucleotide exchange factors (GEFs) have been identified so far which have 
key roles in various intracellular processes ranging from gene expression to intracellular trafficking 
and cytoskeleton rearrangements [43]. It is conceivable that additional pathogenic variants that 
underlie AAS are located in these genes and their identification will be facilitated through establishing 
rigorous phenotyping strategies and analysis of high-throughput sequencing data.  
In this review we have discussed phenotypic and genetic heterogeneity underlying AAS. In the 
majority of cases the condition is associated with germline FGD1 mutations, but many reported cases 
lack a molecular diagnosis and therefore precise clinical diagnosis as AAS cannot be independently 
established. This is of particular importance given extensive phenotypic heterogeneity in AAS and 
phenotypic overlap with other developmental disorders. Therefore, the molecular understanding of this 
condition is substantially incomplete and a more comprehensive approach toward molecular 
identification of causative variants is required. In summary, mutations of FGD1 remains the primary 
molecular candidate for the condition but the burden of pathological variants in either intronic regions 
of FGD1 or related genes, including CDC42, and other genes in relevant pathways merits further 
investigation. 
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